|Bid||0.4120 x 1100|
|Ask||0.4182 x 1300|
|Day's Range||0.4000 - 0.4299|
|52 Week Range||0.3900 - 2.4600|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2023 - Feb 17, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Subscribe to Yahoo Finance Plus to view Fair Value for AEMD
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2022 and provided an update on recent developments.
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter ended September 30, 2022, at 4:15 p.m. EST on Monday, November 14, 2022.